塩野義製薬ShionogiAnnouncestheConductingofDrugDiscoveryCompetition"FINDS"in2008
MSTGは、未来の資産家たちの投資能力を向上させる事を目的とした株式仮想取引ゲームです。
テーマ |  上場企業 |  ニュース |  地域 |  問い合わせ |

 ログイン
ユーザ名:

パスワード:


パスワード紛失
新規登録

 マーケットサマリー
NK22522,451+13.8
TOPIX1,772-4.0
DOW24,753-58.7
NASDAQ7,434+9.4
$/¥109.6-0.06

 MSTGお奨め銘柄
[1515]日鉄鉱業
[3865]北越紀州製紙
[8202]ラオックス
[5563]新日本電工
[6794]フォスター電
[6804]ホシデン

 バーゲン銘柄
[3529]アツギ
[7703]川澄化学工業
[7937]ツツミ
[1914]日本基礎技術
[4033]日東エフシー

 MSTG NEWS

 PR

Check
 上場企業ニュース
塩野義製薬ShionogiAnnouncestheConductingofDrugDiscoveryCompetition"FINDS"in2008

April23,2008Shionogi&Co.ShionogiAnnouncestheConductingofDrugDiscoveryCompetition“FINDS”in2008

Osaka,April23,2008–Shionogi&Co.,Ltd.(HeadOffice:Osaka;President:IsaoTeshirogi)publiclyinvitesresearchersinJapantoentertheirinnovativeideasinitsdrugdiscoverycompetition,FINDS(Pharma-InnovationDiscoverycompetitionShionogi).Shionogistrivesconstantlytoprovidemedicineofthebestpossiblekindessentialforprotectionofthehealthofthepeople.Basedonthispolicy,ithascontinuouslyofferedsuperiormedicinestomanypeople.Tocontinuefulfillingthisobjective,Shionogiiscommittedtofindingnoveldrug“seeds”anddevelopthemforpracticaluse.TheFINDSdrugdiscoverycompetitionwhichstartedinfiscal2007isanewlycollaborativeindustry-academicinitiativeinwhichresearchersinJapanwithinnovativedrugseedscansubmitideasthatmeetShionogi’sspecifiedneedsandworkwiththecompanytodevelopthemintocommerciallyviabledrugs.ThroughFINDS,Shionogiwillworktoenhanceitssourceofnewdrugseedsandbasicdiscoverytechnologiesandstrengthenitssearchcapabilitiesinordertocontinuetodevelopandmanufacturenewdrugsforusearoundtheworld.CompetitionOverview1.Applicationperiod:June2toJune30,20082.Numberofresearchfields:143.Selectionmethod:Two-stageprocessStage1:Preliminaryscreeningtoselectabout30-50candidatesfromonlineapplicationsthroughShionogiwebsite.Stage2:Inprinciple,executionofacomprehensiveconfidentialityagreementfollowedbysubmissionofdetailedwrittenresearchplans,andafinalselectionofabout10projects.4.Selectioncriteria:Submissionswillbeassessedandselectedonthebasisoffactors

1


5.

includingdegreeofcorrespondencewithShionogi’sneeds,originality,practicality,potentialforindustrializationandconflictwithexistingcompanyprojectsResearchbudget:¥2millionto¥5millionperproject(scheduled)(Itisnotforscholarship)

Fordetails,pleaserefertotheattached“ListofApplicableResearchFields.”Forfurtherinformation,contact:PublicRelationsUnitShionogi&Co.,Ltd.(Osaka)Tel.+81-6-6209-7885Fax:+81-6-6229-9596(Tokyo)Tel:+81-3-3406-8164Fax:+81-3-3406-8099###

2


ListofApplicableResearchField
Discoveryofseedsfordrugstotreatmetabolicsyndrome
Identificationoftargetmoleculesusedinthediscoveryofnoveldrugseedsfortreatmentofmetabolicdiseases,includingdiabetesanditsassociatedcomplications,obesity,dyslipidemia,atherosclerosisandchronickidneydiseases.Studyofphysiologicalandpathologicalrolesofnovelmoleculesinanimalsand/orhumans.Establishmentofnovelanimalmodelsrelatedtohumandiseases.Developmentofnoveldrugscreeningtechniques.Otherideasapplicabletodrugdiscoveryinthisfield.

Discoveryofseedsfordrugstotreatallergies
Researchonpromisingdrugsforcontrollingthepredisposingfactorsofallergies,includingTh1/Th2modulators,IgEinhibitorsandimmunotherapy.Otherthemesinthisfield.

Discoveryofseedsforpeptide/protein-basedpharmaceuticals
Seedorleadpeptide/proteinmoleculesaspotentialcandidatesoftherapeuticordiagnosticagentsforinfectiousdisease,pain,metabolicsyndromeorallergosis.

Newdrugdiscoverytechnologiesthatwillleadtonext-generationleading-edgepharmaceuticals
Ideasfornext-generationmolecular-targetedbiopharmaceuticalstoreplaceantibodydrugs,ribozyme,siRNAdrugs,RNAaptamersandothers.Excludedherearegenetherapy,tissueengineeringandcelltherapy.

Efficientandoptimalmethodsforexpressingandisolatingrecombinantproteinswithhighyieldandpurity
Uniquevectorsystem,transfectiontechnique,novelproteinexpressing/synthesizingsystem(especiallyinmammaliancells)tofacilitatethepurificationofrecombinantproteinswithlargequantities.

Novelassaytechnologiesadaptabletohigh-throughputscreening


 情報提供元:http://www.shionogi.co.jp/ir_en/news/detail/e_080423.pdf
 ビジネス関連商品

 PR
利用者が当該情報などに基づいて被ったとされるいかなる損害についても当サイトは責任を負いません。

Copyright (C) 2010 MSTGV.COM. All Rights Reserved.